vs
STANDARD BIOTOOLS INC.（LAB）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
帕可Bio的季度营收约是STANDARD BIOTOOLS INC.的13.9倍（$44.6M vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs -90.4%，领先688.9%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs 13.8%）。STANDARD BIOTOOLS INC.自由现金流更多（$-1.7M vs $-19.9M）。过去两年帕可Bio的营收复合增速更高（7.3% vs -73.4%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
LAB vs PACB — 直观对比
营收规模更大
PACB
是对方的13.9倍
$3.2M
营收增速更快
LAB
高出248.2%
13.8%
净利率更高
LAB
高出688.9%
-90.4%
自由现金流更多
LAB
多$18.3M
$-19.9M
两年增速更快
PACB
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $44.6M |
| 净利润 | $19.3M | $-40.4M |
| 毛利率 | 83.5% | 37.1% |
| 营业利润率 | -578.6% | -92.3% |
| 净利率 | 598.5% | -90.4% |
| 营收同比 | 262.0% | 13.8% |
| 净利润同比 | 156.6% | -1802.7% |
| 每股收益（稀释后） | $0.05 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABPACB
| Q4 25 | $3.2M | $44.6M | ||
| Q3 25 | $19.6M | $38.4M | ||
| Q2 25 | $21.8M | $39.8M | ||
| Q1 25 | $40.8M | $37.2M | ||
| Q4 24 | $890.0K | $39.2M | ||
| Q3 24 | $22.1M | $40.0M | ||
| Q2 24 | $22.5M | $36.0M | ||
| Q1 24 | $45.5M | $38.8M |
净利润LABPACB
| Q4 25 | $19.3M | $-40.4M | ||
| Q3 25 | $-34.7M | $-38.0M | ||
| Q2 25 | $-33.5M | $-41.9M | ||
| Q1 25 | $-26.0M | $-426.1M | ||
| Q4 24 | $-34.1M | $2.4M | ||
| Q3 24 | $-26.9M | $-60.7M | ||
| Q2 24 | $-45.7M | $-173.3M | ||
| Q1 24 | $-32.2M | $-78.2M |
毛利率LABPACB
| Q4 25 | 83.5% | 37.1% | ||
| Q3 25 | 48.5% | 41.4% | ||
| Q2 25 | 48.8% | 36.9% | ||
| Q1 25 | 48.4% | -3.7% | ||
| Q4 24 | -202.8% | 25.6% | ||
| Q3 24 | 54.9% | 25.0% | ||
| Q2 24 | 46.1% | 16.5% | ||
| Q1 24 | 53.1% | 29.1% |
营业利润率LABPACB
| Q4 25 | -578.6% | -92.3% | ||
| Q3 25 | -168.5% | -101.1% | ||
| Q2 25 | -118.1% | -112.8% | ||
| Q1 25 | -80.8% | -1154.5% | ||
| Q4 24 | -1162.1% | -390.1% | ||
| Q3 24 | -120.9% | -160.3% | ||
| Q2 24 | -134.5% | -488.3% | ||
| Q1 24 | -132.2% | -209.6% |
净利率LABPACB
| Q4 25 | 598.5% | -90.4% | ||
| Q3 25 | -177.4% | -98.9% | ||
| Q2 25 | -153.7% | -105.4% | ||
| Q1 25 | -63.8% | -1146.8% | ||
| Q4 24 | -3828.3% | 6.0% | ||
| Q3 24 | -122.0% | -151.9% | ||
| Q2 24 | -203.3% | -481.3% | ||
| Q1 24 | -70.6% | -201.4% |
每股收益（稀释后）LABPACB
| Q4 25 | $0.05 | $-0.11 | ||
| Q3 25 | $-0.09 | $-0.13 | ||
| Q2 25 | $-0.09 | $-0.14 | ||
| Q1 25 | $-0.07 | $-1.44 | ||
| Q4 24 | $-0.06 | $-0.44 | ||
| Q3 24 | $-0.07 | $-0.22 | ||
| Q2 24 | $-0.12 | $-0.64 | ||
| Q1 24 | $-0.27 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.9M | $279.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $424.3M | $5.3M |
| 总资产 | $567.8M | $784.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABPACB
| Q4 25 | $120.9M | $279.5M | ||
| Q3 25 | $129.4M | $298.7M | ||
| Q2 25 | $158.6M | $314.7M | ||
| Q1 25 | $150.9M | $343.1M | ||
| Q4 24 | $166.7M | $389.9M | ||
| Q3 24 | $210.6M | $471.1M | ||
| Q2 24 | $269.8M | $509.8M | ||
| Q1 24 | $287.1M | $561.9M |
总债务LABPACB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $299.0K | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABPACB
| Q4 25 | $424.3M | $5.3M | ||
| Q3 25 | $399.7M | $36.1M | ||
| Q2 25 | $424.5M | $61.5M | ||
| Q1 25 | $454.6M | $91.6M | ||
| Q4 24 | $471.7M | $506.6M | ||
| Q3 24 | $489.3M | $453.1M | ||
| Q2 24 | $510.3M | $492.7M | ||
| Q1 24 | $577.3M | $649.0M |
总资产LABPACB
| Q4 25 | $567.8M | $784.1M | ||
| Q3 25 | $539.6M | $803.2M | ||
| Q2 25 | $557.0M | $825.5M | ||
| Q1 25 | $579.6M | $860.8M | ||
| Q4 24 | $612.3M | $1.3B | ||
| Q3 24 | $681.5M | $1.5B | ||
| Q2 24 | $708.7M | $1.5B | ||
| Q1 24 | $777.7M | $1.7B |
负债/权益比LABPACB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | $-19.9M |
| 自由现金流率自由现金流/营收 | -51.7% | -44.6% |
| 资本支出强度资本支出/营收 | 14.8% | 1.9% |
| 现金转化率经营现金流/净利润 | -0.06× | — |
| 过去12个月自由现金流最近4个季度 | $-82.6M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流LABPACB
| Q4 25 | $-1.2M | $-19.1M | ||
| Q3 25 | $-22.2M | $-18.7M | ||
| Q2 25 | $-20.7M | $-29.4M | ||
| Q1 25 | $-30.3M | $-44.1M | ||
| Q4 24 | $-14.1M | $-30.6M | ||
| Q3 24 | $-27.9M | $-45.5M | ||
| Q2 24 | $-39.0M | $-54.3M | ||
| Q1 24 | $-62.5M | $-75.7M |
自由现金流LABPACB
| Q4 25 | $-1.7M | $-19.9M | ||
| Q3 25 | $-23.1M | $-18.8M | ||
| Q2 25 | $-22.6M | $-29.9M | ||
| Q1 25 | $-35.3M | $-45.4M | ||
| Q4 24 | $-17.4M | $-32.3M | ||
| Q3 24 | $-30.1M | $-46.3M | ||
| Q2 24 | $-41.0M | $-55.7M | ||
| Q1 24 | $-63.3M | $-79.6M |
自由现金流率LABPACB
| Q4 25 | -51.7% | -44.6% | ||
| Q3 25 | -118.1% | -48.9% | ||
| Q2 25 | -103.6% | -75.3% | ||
| Q1 25 | -86.6% | -122.3% | ||
| Q4 24 | -1959.7% | -82.3% | ||
| Q3 24 | -136.4% | -115.7% | ||
| Q2 24 | -182.2% | -154.8% | ||
| Q1 24 | -138.9% | -205.0% |
资本支出强度LABPACB
| Q4 25 | 14.8% | 1.9% | ||
| Q3 25 | 4.5% | 0.2% | ||
| Q2 25 | 8.7% | 1.4% | ||
| Q1 25 | 12.4% | 3.7% | ||
| Q4 24 | 380.0% | 4.1% | ||
| Q3 24 | 10.2% | 2.0% | ||
| Q2 24 | 8.6% | 4.1% | ||
| Q1 24 | 1.7% | 10.0% |
现金转化率LABPACB
| Q4 25 | -0.06× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -12.93× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
暂无分部数据
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
